^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastroesophageal Cancer

    Related cancers:
    4d
    METAGIO: Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France (clinicaltrials.gov)
    P=N/A, N=208, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting | N=500 --> 208
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 negative
    |
    Opdivo (nivolumab)
    4d
    National Cancer Institute "Cancer Moonshot Biobank" (clinicaltrials.gov)
    P=N/A, N=1600, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
    |
    HR positive • MSI-H/dMMR
    5d
    Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Fudan University
    New P2 trial • IO biomarker • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    oxaliplatin • Hetronifly (serplulimab)
    6d
    A Phase 1 Study of the Safety and Tolerability of CTX-10726 (clinicaltrials.gov)
    P1, N=70, Recruiting, Compass Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PD-L1 (Programmed death ligand 1)
    |
    MSI-H/dMMR
    6d
    Spanish Validation of KOQUSS-40 Questionnaire: Assessing QoL of Gastric Cancer Patients After Gastrectomy: SPQUSS-41 (clinicaltrials.gov)
    P=N/A, N=505, Recruiting, Parc de Salut Mar
    New trial
    6d
    Symptom Burden and Healthcare Resource Use in Patients With Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective Review. (PubMed, Clin Med Insights Oncol)
    A mean of 3.4 outpatient visits per patient per month was reported (mean follow-up, 6.5 months), 21.0% of patients had an inpatient admission, and 35.5% had an emergency department visit. This study demonstrates substantial disease-related symptom burden and high HRU for patients with CLDN18.2+, HER2-, LA unresectable or mG/GEJ adenocarcinoma.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 positive • CLDN1 positive
    6d
    Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Nanchong Central Hospital | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    12d
    Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal Carcinoma. (PubMed, JCO Precis Oncol)
    ctDNA testing demonstrates high concordance with tDNA and IHC and offers faster turnaround. Given its minimally invasive nature and strong concordance with tissue-based testing, ctDNA is a reliable tool for genomic profiling and longitudinal monitoring in GEC.
    Retrospective data • Journal • MSi-H Biomarker • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • MSI (Microsatellite instability) • TYK2 (Tyrosine Kinase 2)
    |
    MSI-H/dMMR
    13d
    CP-IVX001: Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=70, Recruiting, ImmVirx Pty Ltd | Trial completion date: Nov 2026 --> Nov 2028 | Trial primary completion date: Sep 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    Tyvyt (sintilimab) • IVX037
    13d
    Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays (clinicaltrials.gov)
    P=N/A, N=420, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    13d
    Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients. (PubMed, Sci Rep)
    To explore whether ultra-sensitive circulating tumor DNA (ctDNA) profiling enables earlier prediction of treatment response and detection of disease progression, we applied NeXT Personal, an ultra-sensitive bespoke tumor-informed liquid biopsy platform, to profile tumor samples from the KeyLargo study, a phase II trial in which metastatic esophagogastric cancer (mEGC) patients received capecitabine, oxaliplatin, and pembrolizumab. Molecular progression (ctDNA increase) preceded imaging-derived progression by a median lead time of 65 days. These results suggest that ultra-sensitive liquid biopsy approaches could improve treatment decision-making for mEGC patients receiving chemotherapy and immunotherapy.
    Journal • Circulating tumor DNA
    |
    NeXT Personal™
    |
    Keytruda (pembrolizumab) • capecitabine • oxaliplatin
    15d
    A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, Astellas Pharma Global Development, Inc.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 expression